Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER1 | P34995 | 6/20 | 0.40 |
| ▸ | DCLRE1B | Q9H816 | 1/20 | 0.33 |
| ▸ | LDHA | P00338 | 1/20 | 0.33 |
| ▸ | CSNK1D | P48730 | 3/20 | 0.33 |
| ▸ | CSNK1E | P49674 | 3/20 | 0.33 |
| ▸ | DHODH | Q02127 | 2/20 | 0.33 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | CDC7 | O00311 | 1/20 | 0.32 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.32 |
| ▸ | KMO | O15229 | 1/20 | 0.32 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4329361 | 0.88 | CYP1A2 (0.37) | PTGER1DHODHKDM4EALDH1A1 | |
| SCHEMBL4331950 | 0.86 | CTSA (0.37) | PTGER1CSNK1DCSNK1E | |
| SCHEMBL4140638 | 0.82 | NPC1 (0.32) | — | |
| SCHEMBL4348125 | 0.82 | PTGER1 (0.41) | PTGER1LDHACSNK1DCSNK1EDHODH | |
| SCHEMBL4335926 | 0.81 | IKBKB (0.35) | PTGER1 | |
| SCHEMBL4341027 | 0.80 | KDM4E (0.40) | KDM4EALDH1A1 | |
| SCHEMBL4340947 | 0.79 | PTGER1 (0.36) | PTGER1DCLRE1BCSNK1DCSNK1EDHODH | |
| SCHEMBL4341004 | 0.79 | PTGER1 (0.36) | PTGER1DCLRE1BCSNK1DCSNK1EDHODH | |
| SCHEMBL4334945 | 0.78 | CSNK1E (0.38) | PTGER1DCLRE1BCSNK1DCSNK1EDHODH | |
| SCHEMBL4339201 | 0.77 | JAK2 (0.38) | PTGER1DCLRE1BCSNK1DCSNK1EDHODH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7541376-B2 | 1H-indazole compounds | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-06-02 | — | — | US | disclosed |
| US-20050282880-A1 | Novel 1H-indazole compounds | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2005-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050282880-A1 | Novel 1H-indazole compounds | MAPK1, MAPK3, MAPK13 | PTGER1 3143/4885DCLRE1B 4617/4885LDHA 3498/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.